Enables several functions, including PDZ domain binding activity; amyloid-beta binding activity; and ligand-gated monoatomic ion channel activity. Involved in several processes, including cellular response to brain-derived neurotrophic factor stimulus; cellular response to glycine; and modulation of chemical synaptic transmission. Located in several cellular components, including asymmetric synapse; dendrite; and distal axon. Part of AMPA glutamate receptor complex. Is active in Schaffer collateral - CA1 synapse; glutamatergic synapse; and synaptic membrane. Biomarker of status epilepticus. Orthologous to human GRIA2 (glutamate ionotropic receptor AMPA type subunit 2); PARTICIPATES IN N-cadherin signaling pathway; amyotrophic lateral sclerosis pathway; glutamate signaling pathway; INTERACTS WITH (+)-pilocarpine; (S)-AMPA; 1-(4-methoxybenzyl)-3-(5-nitro-1,3-thiazol-2-yl)urea.
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA
[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein, Genistein inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA
SNAP25 protein affects the reaction [Benzo(a)pyrene results in decreased expression of GRIA2 mRNA], SNAP25 protein affects the reaction [Benzo(a)pyrene results in decreased expression of GRIA2 protein]
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA
[Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GRIA2 protein]
[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein, Genistein inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein]
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA
[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein, Genistein inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA
[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein, Genistein inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of GRIA2 protein]
Kainic Acid binds to and results in increased activity of GRIA2 protein, Urethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA2 protein]
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA2 mRNA], RG108 inhibits the reaction [Kainic Acid results in increased methylation of GRIA2 gene]
[[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA, [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA
[[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA
[Lead co-treated with Tetrodotoxin] results in increased expression of [GRIA1 protein binds to GRIA2 protein], BDNF protein inhibits the reaction [Lead results in decreased expression of GRIA2 protein]
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA
perfluorooctane sulfonic acid results in decreased expression of GRIA2 mRNA, perfluorooctane sulfonic acid results in decreased expression of GRIA2 protein
perfluorooctane sulfonic acid results in increased expression of and affects the localization of GRIA2 protein, perfluorooctane sulfonic acid results in increased expression of and affects the localization of GRIA2 protein modified form
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRIA2 mRNA
[[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA, [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of GRIA2 mRNA
Ultrastructural localisation and differential agonist-induced regulation of AMPA and kainate receptors present at the presynaptic active zone and postsynaptic density.
CaMKII-dependent dendrite ramification and spine generation promote spatial training-induced memory improvement in a rat model of sporadic Alzheimer's disease.
Brain-derived neurotrophic factor signal enhances and maintains the expression of AMPA receptor-associated PDZ proteins in developing cortical neurons.
Alpha7 nicotinic acetylcholine receptors occur at postsynaptic densities of AMPA receptor-positive and -negative excitatory synapses in rat sensory cortex.
Brain-derived neurotrophic factor regulates surface expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptors by enhancing the N-ethylmaleimide-sensitive factor/GluR2 interaction in developing neocortical neurons.
histones (e.g. H4) associated with the promoters in hippocampal CA3 neurons after seizures, are rapidly deacetylated, and a histone deacetylase inhibitor, trichostatin A, inhibits and quickly reverses deacetylation
